Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer

Leisha A Emens¹, Sylvia Adams², Ashley Cimino-Mathews³, Mary L Disis⁴, Margaret E Gatti-Mays⁵, Alice Y Ho⁶, Kevin Kalinsky⁷, Heather L McArthur⁸, Elizabeth A Mittendorf^{9

10}, Rita Nanda¹¹, David B Page¹², Hope S Rugo¹³, Krista M Rubin¹⁴, Hatem Soliman¹⁵, Patricia A Spears¹⁶, Sara M Tolaney¹⁷, Jennifer K Litton¹⁸

Affiliations

¹ Department of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA jlitton@mdanderson.org emensla@upmc.edu.
² Perlmutter Cancer Center, New York University Langone, New York, New York, USA.
³ Department of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁴ Cancer Vaccine Institute, University of Washington, Seattle, Washington, USA.
⁵ Pelotonia Institute for Immuno-Oncology, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
⁶ Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁷ Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
⁸ Department of Medicine, UT Southwestern, Dallas, Texas, USA.
⁹ Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
¹⁰ Breast Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
¹¹ Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, USA.
¹² Earle A Chiles Research Institute, Portland, Oregon, USA.
¹³ Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
¹⁴ Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
¹⁵ Department of Breast Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
¹⁶ University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA.
¹⁷ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
¹⁸ Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA jlitton@mdanderson.org emensla@upmc.edu.

PMID: 34389617
PMCID: PMC8365813
DOI: 10.1136/jitc-2021-002597

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer

Leisha A Emens et al. J Immunother Cancer. 2021 Aug.

. 2021 Aug;9(8):e002597.

doi: 10.1136/jitc-2021-002597.

Authors

Affiliations

¹ Department of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA jlitton@mdanderson.org emensla@upmc.edu.
² Perlmutter Cancer Center, New York University Langone, New York, New York, USA.
³ Department of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁴ Cancer Vaccine Institute, University of Washington, Seattle, Washington, USA.
⁵ Pelotonia Institute for Immuno-Oncology, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
⁶ Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁷ Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
⁸ Department of Medicine, UT Southwestern, Dallas, Texas, USA.
⁹ Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
¹⁰ Breast Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
¹¹ Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, USA.
¹² Earle A Chiles Research Institute, Portland, Oregon, USA.
¹³ Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
¹⁴ Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
¹⁵ Department of Breast Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
¹⁶ University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA.
¹⁷ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
¹⁸ Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA jlitton@mdanderson.org emensla@upmc.edu.

PMID: 34389617
PMCID: PMC8365813
DOI: 10.1136/jitc-2021-002597

Erratum in

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
[No authors listed] [No authors listed] J Immunother Cancer. 2021 Dec;9(12):e002597corr1. doi: 10.1136/jitc-2021-002597corr1. J Immunother Cancer. 2021. PMID: 34862255 Free PMC article. No abstract available.

Abstract

Breast cancer has historically been a disease for which immunotherapy was largely unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with chemotherapy for the treatment of advanced/metastatic triple-negative breast cancer (TNBC) has demonstrated efficacy, including longer progression-free survival and increased overall survival in subsets of patients. Based on clinical benefit in randomized trials, ICIs in combination with chemotherapy for the treatment of some patients with advanced/metastatic TNBC have been approved by the United States (US) Food and Drug Administration (FDA), expanding options for patients. Ongoing questions remain, however, about the optimal chemotherapy backbone for immunotherapy, appropriate biomarker-based selection of patients for treatment, the optimal strategy for immunotherapy treatment in earlier stage disease, and potential use in histological subtypes other than TNBC. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). The expert panel drew upon the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for breast cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence-based and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with breast cancer.

Keywords: breast neoplasms; clinical trials as topic; guidelines as topic; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SA–Contracted research: Funding to institution from Amgen, Bristol Myers Squibb, Merck, Celgene, Roche. AC-M–Consulting fees: Bristol Myers Squibb, Roche Diagnostics; Contracted research: Bristol Myers Squibb; Partner Salary: Vivante Health; Royalty: Springer/Demos Publishing-Textbooks. MLD–Contracted research: Pfizer, EMD Serono, Bavarian Nordisk, Precigen, Epithany, Silverback Therapeutics, Celgene; IP Rights: University of Washington; Non-CME Services: SITC; Ownership interest: Epithany; Partner ownership interest: Epithany; Partner salary: Cox Cable; Royalty: University of Washington; Salary: University of Washington. LAE–Contracted research: Aduro Biotech, AstraZeneca, Bristol Myers Squibb, Corvus, EMD Serono, Genentech, F Hoffman La Roche, Maxcyte, Merck, Tempest, Silverback, Bolt, Compugen, Takeda, CytomX; Consulting fees: Genentech, F Hoffman La Roche, Syndax, Lilly, AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Chugai, F Hoffman La Roche, GCPR, Genentech, Gilead, Gritstone, Medimmune, Macrogenics, Novartis, Peregrine, Replimune, Shionogi, Silverback, Vaccinex; IP Rights: Aduro Biotech; Royalty: Elsevier; Salary: University of Pittsburgh, UPMC UPP; Grants from non-industry entities: HeritX Incorporated, NSABP Foundation, Translational Breast Cancer Research Consortium, Breast Cancer Research Foundation, National Cancer Institute, Department of Defense, Johns Hopkins University, University of California San Francisco, Cornell University; Ownership interest: Molecuvax-potential for royalties in the future. MG-M–Trial funding to institution: EMD Serono (OSU Site PI). AYH–Consulting fees: Seattle Genetics; La Roche-Posay; Contracted research: Merck and GSK. KK–Consulting fees: Eli Lilly, Pfizer, Novartis, Eisai, AstraZeneca, Merck, Seattle Genetics; Contracted research: Incyte, Genentech, Eli Lilly, Pfizer, Calithera Biosciences, Acetylon, Seattle Genetics, Amgen, ZenoPharmaceuticals, CytomX Therapeutics; Partner Salary: Pfizer, Array Biopharma - no longer employee at either; Speaker Bureau: Eli Lilly. JKL–Contracted research: Novartis, Medivation/Pfizer, Genentech, GSK, EMD Serono, AstraZeneca, Medimmune, Zenith, Jounce (All were payments to my Institution of for writing support for manuscripts of multicenter trials. No payments directly to Dr Litton); Consulting fees: Pfizer/Medivation, AstraZeneca, Ayala (All honorariums were refused); Salary: The University of Texas MD Anderson Cancer Center. HLM–Consulting fees: Bristol Myers Squibb, Eli Lilly, Genentech/Roche, Merck, Pfizer, Puma, Daiichi Sankyo, Seattle Genetics, AstraZeneca; Contracted Research: Bristol Myers Squibb, MedImmune, LLC/AstraZeneca, BTG, Merck. EAM–Consulting fees: Merck, Genomic Health, Roche/Genentech; Contracted research: GlaxoSmithKline; NPI: 1831388596. RN–Consulting fees: Clovis, Immunomedics, Macrogenics, Merck, Pfizer, Seattle Genetics; Contracted research: AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Odonate Therapeutics, Pfizer, Seattle Genetics; DSMB: G1 Therapeutics. DBP–Consulting fees: Genentech, Merck, Brooklyn Immunotherapeutics; Contracted research: Merck, Brooklyn Immunotherapeutics, Bristol Myers Squibb; Speaker bureau: Genentech, Novartis. HSR–Consulting fees: Puma, Samsung - Limited consulting; Contracted research: Pfizer, Merck, Novartis, Lilly, Genentech, OBI, Odonate, Daiichi, Seattle Genetics, Eisai, Macrogenics, Immunomedics; Travel support for educational programs: Daiichi, Mylan, Pfizer, Merck, AstraZeneca, Novartis, Macrogenics. KMR–Consulting fees: Merck, Bristol Myers Squibb, Eisai. HS–Consulting fees: AstraZeneca, Eisai, Novartis, Celgene, PUMA, Seattle Genetics. PAS–Consulting fees: Pfizer. SMT–Consulting fees: AstraZeneca, Eli Lilly, Merck, Nektar, Novartis, Pfizer, Genentech, Immunomedics, Bristol Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Celldex, Paxman, Odonate, Seattle Genetics, Silverback Therapeutics, G1 Therapeutics, AbbVie, Anthenex, Oncopep; Contracted research: AstraZeneca, Eli Lilly, Merck, Nektar, Novartis, Pfizer, Genentech, Immunomedics, Bristol Myers Squibb, Eisai, Nanostring, Sanofi, Exelisis, Seattle Genetics, Cyclacel, Odonate. SITC Staff: SMW—Shares owned: Pacific Biosciences of California, Editas Medicine. EG, AK, LL—Nothing to disclose.

References

1. Berry DA, Cronin KA, Plevritis SK, et al. . Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med Overseas Ed 2005;353:1784–92. 10.1056/NEJMoa050518 - DOI - PubMed
1. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med Overseas Ed 2012;367:1998–2005. 10.1056/NEJMoa1206809 - DOI - PubMed
1. Helvie MA, Bevers TB. Screening mammography for average-risk women: the controversy and NCCN's position. J Natl Compr Canc Netw 2018;16:1398–404. 10.6004/jnccn.2018.7081 - DOI - PubMed
1. Munoz D, Near AM, van Ravesteyn NT, et al. . Effects of screening and systemic adjuvant therapy on ER-specific us breast cancer mortality. J Natl Cancer Inst 2014;106. 10.1093/jnci/dju289. [Epub ahead of print: 24 09 2014]. - DOI - PMC - PubMed
1. Zielonke N, Gini A, Jansen EEL, et al. . Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: a systematic review. Eur J Cancer 2020;127:191–206. 10.1016/j.ejca.2019.12.010 - DOI - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer

Affiliations

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer

Authors

Affiliations

Erratum in

Abstract

Conflict of interest statement

References

MeSH terms

LinkOut - more resources

Full Text Sources